Skip to content
10-Q

Quarterly Report

Endo, Inc.

0002008861-25-000014

← back to feed
Filed
May 12, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 5, 2025 76.31M sh
Shares Diluted Q1 2025 · Mar 31, 2025 76.21M sh
Capex Q1 2025 · Mar 31, 2025 $13.62M
Operating Cash Flow Q1 2025 · Mar 31, 2025 $1.13M
Long Term Debt Q1 2025 · Mar 31, 2025 $2.42B
Long Term Debt Q1 2025 · Dec 31, 2024 $2.42B
Short Term Debt Q1 2025 · Mar 31, 2025 $15M
Short Term Debt Q1 2025 · Dec 31, 2024 $15M
Cash And Equivalents Q1 2025 · Mar 31, 2025 $369.68M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $387.25M
Stockholders Equity Q1 2025 · Mar 31, 2025 $1.13B
Stockholders Equity Q1 2025 · Dec 31, 2024 $1.25B
Stockholders Equity Q1 2025 · Mar 31, 2024 −$6.75B
Stockholders Equity Q1 2025 · Dec 31, 2023 −$6.6B
Current Liabilities Q1 2025 · Mar 31, 2025 $491.79M
Current Liabilities Q1 2025 · Dec 31, 2024 $514.99M
Current Assets Q1 2025 · Mar 31, 2025 $1.45B
Current Assets Q1 2025 · Dec 31, 2024 $1.48B
Total Assets Q1 2025 · Mar 31, 2025 $4.19B
Total Assets Q1 2025 · Dec 31, 2024 $4.35B
Eps Diluted Q1 2025 · Mar 31, 2025 −$1.69
Eps Basic Q1 2025 · Mar 31, 2025 −$1.69
Sga Expense Q1 2025 · Mar 31, 2025 $149.04M
Net Income Q1 2025 · Mar 31, 2025 −$128.63M
Net Income Q1 2025 · Mar 31, 2024 −$154.23M
Cost Of Revenue Q1 2025 · Mar 31, 2025 $295.4M
Revenue Q1 2025 · Mar 31, 2025 $392.83M